



Bloom Burton & Co.
Healthcare Investor Conference
June 17 - 18, 2014



bloom burton & co

/accelerating returns in healthcare



bloom burton & co

/accelerating returns in healthcare

We gratefully acknowledge the support of our sponsors

Gold sponsors



People who know, know BDO.SM



TROUTMAN SANDERS

Silver sponsors



Cancer Breakthroughs.
Realized.



Toronto Stock
Exchange

TSX Venture
Exchange

Welcome to the 2014 Bloom Burton & Co. Healthcare Investor Conference

Bloom Burton exists to accelerate returns in healthcare, and there is no better illustration than this very conference, which brings together hundreds of entrepreneurs and investors to meet, learn and plan for growth.

This has been an exciting year for the Canadian healthcare sector, with financing and corporate activity at decade highs, the launch and recapitalization of many venture capital funds, strong overall returns in the stock market, and support from multi-national firms and government. This has also been an unprecedented year for Bloom Burton! We have doubled our office space and the number of professionals at our firm, we served even more company and investor clients through our investment banking, research and consulting work, and we launched our asset management platform with two direct investment funds, providing equity and debt solutions to Canadian healthcare companies.

Most of all, we are so proud of our talented and dedicated team, who work with such dedication to serve our clients. We strive to produce exceptional deliverables and outcomes. And we are here for you today as you meet and plan for the success of the healthcare sector in Canada.

Have a wonderful day!

Brian and Jolyon



Network: TRBOT
Username: ob
Password: ob123

Corporate presentations will be available via a weblink to be emailed to attendees after the conference.





Bloom Burton & Co. Pre-Venture Symposium June 17, 2014

Time	Event
8:00AM	Registration and Continental Breakfast
8:30AM	Welcome and Introductory Remarks
8:40AM	Sponsor Panel Moderator: JOLYON BURTON , Bloom Burton & Co.
9:30-10:10AM	<div style="display: flex; justify-content: space-around;"> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">9:30AM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">9:50AM</div> </div> Spartan Bioscience Intellijoint Surgical
10:10AM	Coffee Break & Networking
10:40-12:00PM	<div style="display: flex; justify-content: space-between;"> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">10:40AM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">11:00AM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">11:20AM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">11:40AM</div> </div> Induce Biologics viDA Therapeutics Fusion Pharmaceuticals Actium Research
12:00PM	Lunch
12:30PM	Lunch Panel - Venture Capitalists Moderator: BRIAN BLOOM , Bloom Burton & Co.
1:20-2:20PM	<div style="display: flex; justify-content: space-around;"> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">1:20PM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">1:40PM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">2:00PM</div> </div> Newtopia Colibri Technologies Vasomune Therapeutics
2:20PM	Coffee Break & Networking
2:50-3:45PM	<div style="display: flex; justify-content: space-around;"> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">2:50PM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">3:10PM</div> <div style="background-color: black; color: white; padding: 2px 5px; font-weight: bold;">3:30PM</div> </div> Matrizyme Pharma Medi+Sure Canada Alentic Microscience
3:45PM	Afternoon Panel - Business Development with Big Pharma Moderator: ARMAND BALBONI , Bloom Burton & Co.
5:30PM	Cocktail Party at Steam Whistle Brewing 255 Bremner Blvd., Toronto

Bloom Burton & Co. Healthcare Investor Conference June 18, 2014

Time	Event		
8:00AM	Registration and Continental Breakfast		
	Welcome and Introductory Remarks Speaker: JOLYON BURTON , CEO & Head of Investment Banking, Bloom Burton & Co.		
8:30AM	Keynote Speech Speaker: AVIK S. A. ROY , Managing Partner, Roy Healthcare Research		
	Room A/B	Room C/D	Lounge
9:30AM	Aquinox Pharmaceuticals	Pharmascience	Zymeworks
10:00AM	Trillium Therapeutics	Cipher Pharmaceuticals	Xagenic
10:30AM	Lorus Therapeutics	Paladin Labs	Antibe Therapeutics
11:00AM	Oncolytics Biotech	Concordia Healthcare	CRH Medical
11:30AM	Æterna Zentaris	Knight Therapeutics	ESSA Pharma
	Lunch & Discussion Buyside Investors Panel: How Healthcare Companies Can Attract Buyside Interest Moderator: BRIAN BLOOM , President & Head of Institutional Sales, Bloom Burton & Co.		
12:00PM			
	Room A/B	Room C/D	Lounge
1:30PM	ProMetic Life Sciences	Merus Labs	Nuvo Research
2:00PM	Tekmira Pharmaceuticals	LifeLabs	Agility Health
2:30PM	Trimel Pharmaceuticals	Novadaq Technologies	STI Technologies
3:00PM	Aurinia Pharmaceuticals	Centric Health	PediaPharm
3:30PM	BELLUS Health	Cardiome Pharma	Bioniche Life Sciences
4:00PM	Transition Therapeutics	Tribute Pharmaceuticals	Patient Home Monitoring
4:30PM	Sophiris Bio	BioSyent	Response Biomedical







Actium Research

JUNE 17, 2014 11:40AM
MAIN BALLROOM

Private

Actium is a private biotechnology company exploiting unique stem cell technology to develop cancer therapeutics, and regenerative medicine drugs. Actium's mission is to identify and develop breakthrough drugs and technologies to fulfill critical needs of physicians and patients in treating severe diseases and tissue damage.

Æterna Zentaris

JUNE 18, 2014 11:30AM
ROOM A/B

TSX:AEZ, NASDAQ:AEZS

Æterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development.

Agility Health

JUNE 18, 2014 2:00PM
LOUNGE

TSXV: AHI

Agility Health is at the forefront of providing high-value rehabilitation solutions, including physical therapy, occupational therapy, speech pathology services and clinical management software to healthcare providers and employers across the United States.

Alentic Microscience

JUNE 17, 2014 3:30PM
MAIN BALLROOM

Private

Alentic Microscience Inc. is pioneering lensless microscopy, developing new methods and instrumentation for biomedical, industrial and other applications.



Antibe Therapeutics

JUNE 18, 2014 10:30AM
LOUNGE

TSXV: ATE

Antibe Therapeutics is a human drug development company with a portfolio of patented anti-inflammatory drug candidates targeting significant global markets. Antibe's portfolio of patented drugs includes versions of existing anti-inflammatory drugs modified with the goal of improving safety. Our lead drug, ATB-346, targets the global need for a safe anti-inflammatory painkiller.

Aquinox Pharmaceuticals

JUNE 18, 2014 9:30AM
ROOM A/B

NASDAQ: AQXP

Aquinox Pharmaceuticals, Inc. is a clinical stage pharmaceutical company discovering and developing novel, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase 1 ("SHIP1") for the treatment of inflammatory disease and cancer.

Aurinia Pharmaceuticals

JUNE 18, 2014 3:00PM
ROOM A/B

TSXV: AUP

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. Its lead drug, voclosporin, is a novel calcineurin inhibitor. Many members of Aurinia's current leadership team are former senior managers of Aspreva Pharmaceuticals ("Aspreva"), which Galenica acquired for C\$915 million in 2008. While at Aspreva, this management team executed one of the largest and most important lupus nephritis studies ever conducted, called the Aspreva Lupus Management Study ("ALMS"), which resulted in the emergence of mycophenolate mofetil as a new standard treatment for patients suffering from this devastating and potentially fatal disease.

BELLUS Health

JUNE 18, 2014 3:30PM
ROOM A/B

TSX: BLU

BELLUS Health is a drug development company focused on rare diseases. It has a portfolio of rare disease projects including KIIACTA™ in Phase III for AA amyloidosis, KIIACTA™ for sarcoidosis, clinical stage Shigamab™ for sHUS and a research-stage project for AL amyloidosis. The lead program KIIACTA™ is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIIACTA™ is partnered with global private equity firm Auvén Therapeutics.



Bioniche Life Sciences

JUNE 18, 2014 3:30PM
LOUNGE

TSX: BNC

Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company's anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.

Biosyent

JUNE 18, 2014 4:30PM
ROOM C/D

TSXV: RX

BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

Cardiome Pharma

JUNE 18, 2014 3:30PM
ROOM C/D

TSX: COM, NASDAQ: CRME

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for the treatment of acute coronary syndrome patients.

Centric Health

JUNE 18, 2014 3:00PM
ROOM C/D

TSX: CHH

Centric Health's vision is to be Canada's premier healthcare company, providing innovative solutions centered on patients and healthcare professionals. As a diversified healthcare company with investments in several niche service areas, Centric Health currently has operations in medical assessments, disability and rehabilitation management, physiotherapy and surgical centres, homecare, specialty pharmacy and wellness and prevention. With knowledge and experience of healthcare delivery in international markets and extensive and trusted relationships with payers, physicians, and government agencies, Centric Health is pursuing expansion opportunities into other healthcare sectors to create value for all stakeholders with an unwavering commitment to the highest quality of care.



Cipher Pharmaceuticals

JUNE 18, 2014 10:00AM
ROOM C/D

TSX: DND

Cipher Pharmaceuticals is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may market the product ourselves. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since the Company was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed six marketing partnerships, generating growing licensing revenue.

Colibri Technologies

JUNE 17, 2014 1:40PM
MAIN BALLROOM

Private

Colibri Technologies is dedicated to developing technologies that will improve patient quality of life, reduce healthcare costs and enable better treatment options for large patient populations. Our goal is to make cardiac procedures safer, faster, cheaper and more effective through image guidance.

Concordia Healthcare

JUNE 18, 2014 11:00AM
ROOM C/D

TSX: CXR, OTCQX: CHEHF

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay®(clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia has recently completed the acquisition of Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome and acute enterocolitis. Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.

CRH Medical

JUNE 18, 2014 11:00AM
LOUNGE

TSX: CRH, OTCQX: CRMMF

CRH Medical Corporation is North American company focused on providing physicians with innovative products for the treatment of gastrointestinal diseases. The Company's product, the CRH O'Regan System, is a single use, disposable, hemorrhoid treatment that is safe and highly effective in treating hemorrhoid grades I - IV. The O'Regan System is rapidly emerging as the standard of care with gastroenterologists who treat hemorrhoids. In addition to the product, CRH Medical delivers clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web-based platform to connect doctors with patients as well as educating its ever increasing install base of physicians.



ESSA Pharma

JUNE 18, 2014 11:30AM
LOUNGE

Private

ESSA is developing drugs which selectively block the N-terminus of the androgen receptor, potentially bypassing all the known mechanisms of Castrate-Resistant Prostate Cancer, providing recurrent prostate cancer patients the potential for significant increases in progression-free survival.

Fusion Pharmaceuticals

JUNE 17, 2014 11:20AM
MAIN BALLROOM

Private

Fusion Pharmaceuticals is a radiopharmaceutical company spun out from Centre for Probe Development and Commercialization (CPDC) that develops proprietary, tailored products which utilize validated vehicles to deliver true personalized medicine (i.e., imaging, selection, treatment and monitoring of patients) for patients with unmet medical needs.

Induce Biologics

JUNE 17, 2014 10:40AM
MAIN BALLROOM

Private

Induce Biologics Inc. is a regenerative medicine company based in Toronto, Canada, that is developing bioimplants for bone regeneration. The lead product candidate, URIST™, is a novel implant that contains bone morphogenetic protein (BMP), and a proprietary carrier; this carrier provides a gradual, multi-phasic delivery of BMP. This gradual delivery allows for the use of less BMP compared to current products, making it more cost-effective. Also, since all known BMP adverse events and toxicity issues have been related to higher doses of BMP, the ability to use lower doses provides a potential risk benefit as well.

Intellijoint Surgical

JUNE 17, 2014 9:50AM
MAIN BALLROOM

Private

Intellijoint HIP™ is a proprietary miniaturized system that is intended to help surgeons in the selection and positioning of orthopaedic implants during hip replacement surgery. Intellijoint HIP™ consists of 2 disposable sensors (1 sensor, 1 marker) and a display unit. With Intellijoint HIPTM, surgeons are able to increase the accuracy of hip replacement surgery. It's an instrument that assists them to make the critical measurements that studies in computer assisted surgery have shown to enhance clinical outcomes.



Knight Therapeutics

JUNE 18, 2014 11:30AM
ROOM C/D

TSX: GUD

Knight Therapeutics Inc is a publicly-traded, specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products. Knight conducts late-stage clinical development on low risk, low expense product opportunities. All of Knight's products are sourced through partnerships.

LifeLabs

JUNE 18, 2014 2:00PM
ROOM C/D

Private

LifeLabs is a Canadian-owned company and is the country's largest provider of community laboratory services with over 50 years of experience providing laboratory testing services to help health care providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in health care. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, serving 19 million patients annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure.

Lorus Therapeutics

JUNE 18, 2014 10:30AM
ROOM A/B

TSX: LOR

Lorus is a clinical-stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies.

Matrizyme Pharma

JUNE 17, 2014 2:50PM
MAIN BALLROOM

Private

Matrizyme Pharma Corporation, a Canadian-based biopharmaceutical company, has developed an innovative therapy, MZ-004, to facilitate angioplasty in patients suffering with chronic total occlusions. Chronic total occlusions that cannot be opened with conventional PCI techniques are the main reason patients are referred for coronary artery bypass surgery. Cardiovascular disease remains one of the leading causes of mortality in the western world and MZ-004 may offer patients a unique treatment option thereby avoiding open heart surgery or long term medical management of their cardiovascular condition.



Medi+Sure Canada

JUNE 17, 2014 3:10PM
MAIN BALLROOM

Private

Medi+Sure Canada Inc., is committed to bringing value to the high cost of Diabetes - both to the patient and to their insurers. Our high quality, affordable Medi+Sure™ diabetic blood glucose meters & test strips are now licensed for sale across Canada. Our goal is to bring significant savings to all Provincial Drug Plans on their current test strip purchases while delivering world class training to and Diabetic Patient Education support to those living with diabetes. Our commitment is to always be the High Quality, affordable Health Canada licensed blood glucometer and strip line. Our affordable quality products bring economic value to the Diabetes testing market, enabling patients and payers to reduce their healthcare spending.

Merus Labs

JUNE 18, 2014 1:30PM
ROOM C/D

TSX: MSL, NASDAQ: MSLI

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

Newtopia

JUNE 17, 2014 1:20PM
MAIN BALLROOM

Private

Newtopia is a personalized health company dedicated to inspiring individuals to make the right lifestyle decisions to live healthy. Newtopia believes science, good habits and friendly, professional support are important ingredients in designing a program to best meet clients' goals. Newtopia's health engagement platform leverages genetic testing and the latest engagement science to build highly personalized lifestyle plans that deliver sustainable results. We work with corporations and brands to improve the health of risk-assessed individuals while lowering meaningful health care costs and delivering a strong ROI. Newtopia's programs and products are guideline and evidence based and are available across the United States and Canada.

Novadaq Technologies

JUNE 18, 2014 2:30PM
ROOM C/D

TSX: NDQ, NASDAQ: NVDQ

Enabling medical professionals with clinically relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is NOVADAQ's global mission. SPY® fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 100 peer-reviewed publications demonstrate that the use of SPY imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.



Nuvo Research

JUNE 18, 2014 1:30PM
LOUNGE

TSX: NRI

Nuvo is a specialty pharmaceutical company with a diverse portfolio of products and technologies. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four U.S. Food and Drug Administration (FDA) approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the creation of patented formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders.

Oncolytics Biotech

JUNE 18, 2014 11:00AM
ROOM A/B

TSX: ONC, NASDAQ: ONCY

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus.

Paladin Labs

JUNE 18, 2014 10:30AM
ROOM C/D

NASDAQ: ENDP

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies.

Patient Home Monitoring

JUNE 18, 2014 4:00PM
LOUNGE

TSXV: PHM

PHM is an acquisition-oriented, fast-growing and profitable company servicing patients with heart disease and other chronic health conditions. PHM is focused on acquiring companies in a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity.



PediaPharm

JUNE 18, 2014 3:00PM
LOUNGE

TSXV: PDP

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company's innovative product portfolio includes NYDA[®]; a breakthrough treatment for head lice; EpiCeram[®] a non-steroid emulsion for eczema; KoolEffect[™] which reduces the symptoms of fever; and VapoLyptus[™]; a soothing vapour patch of Eucalyptus and Camphor.

Pharmascience

JUNE 18, 2014 9:30AM
ROOM C/D

Private

Founded in 1983, Pharmascience is a leading manufacturer of generic drugs in a wide range of therapeutic categories. We are a privately owned company with technologically sophisticated operations designed to satisfy customer expectations for quality products and responsive service. Our state-of-the-art R&D laboratory and production facilities are located in Montreal, Quebec. Our Canada-wide customer base includes pharmacists, drug wholesalers and major retailers.

ProMetic Life Sciences

JUNE 18, 2014 1:30PM
ROOM A/B

TSX: PLI, OTCQX: PFSCF

ProMetic Life Sciences Inc. is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/ inflammation. A number of both the plasma-derived and small molecule products are under development for orphan drug indications.

Response Biomedical

JUNE 18, 2014 4:30PM
LOUNGE

TSX: RBM, OTCQB: RPBIF

Response Biomedical Corp., based in Vancouver, Canada, was founded in 1992. Response develops, manufactures and markets rapid on-site diagnostic tests at its world class manufacturing facility in Vancouver, Canada, for use on the RAMP® Platform. The RAMP® Platform is sold worldwide and includes a variety of testing applications in the cardiovascular, infectious disease, biodefense and environmental arenas. The RAMP® Platform provides laboratory quality results with the speed, precision and accuracy that many hospitals expect of their central lab systems. It is ideally suited for both point of care testing and laboratory use. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories.



Sophiris Bio

JUNE 18, 2014 4:30PM
ROOM A/B

NASDAQ: SPHS

Sophiris Bio Inc. is a biopharmaceutical company developing treatments for urologic diseases. PRX302 is a targeted treatment in Phase 3 development for the symptoms of benign prostatic hyperplasia (BPH) or enlarged prostate. PRX302 is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing BPH treatments.

Spartan Bioscience

JUNE 17, 2014 9:30AM
MAIN BALLROOM

Private

Spartan Bioscience is the leader in on-demand DNA testing. Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan's technology fully integrates DNA collection, extraction and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand.

STI Technologies

JUNE 18, 2014 2:30PM
LOUNGE

Private

STI connects physicians, patients, pharmacy and pharma with a variety of card-based programs empowering choice amongst healthcare professionals and patients, ultimately improving patient outcomes. We facilitate valuable interactions between each of these four distinct groups, using our advanced patient-centric technology platform to power all of our solutions.

Tekmira Pharmaceuticals

JUNE 18, 2014 2:00PM
ROOM A/B

TSX: TKM, NASDAQ: TKMR

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs.



Transition Therapeutics

JUNE 18, 2014 4:00PM
ROOM A/B

TSX: TTH, NASDAQ: TTHI

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The Company's lead CNS drug candidate is ELND005 for the treatment of Alzheimer's disease and Down syndrome. Transition's lead metabolic drug candidate is TT-401 (LY2944876) for the treatment of type 2 diabetes and accompanying obesity.

Tribute Pharmaceuticals

JUNE 18, 2014 4:00PM
ROOM C/D

TSXV: TRX, OTCQB: TBUFF

Tribute Pharmaceuticals Canada Inc., a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. Tribute Pharmaceuticals Canada Inc.'s current portfolio of assets includes six products: NeoVisc®, Uracyst®, Bezalip® SR, Soriatane®, Cambia®, and Collatamp G®. Each of these products has received regulatory approval in Canada.

Trillium Therapeutics

JUNE 18, 2014 10:00AM
ROOM A/B

TSX: TR, OTCQX: SCTPF

Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp. TSX:SSS) is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRP α Fc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRP α Fc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies.

Trimel Pharmaceuticals

JUNE 18, 2014 2:30PM
ROOM A/B

TSX: TRL

Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. The Corporation holds a licence for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system ("TriVair™").



Vasomune Therapeutics

JUNE 17, 2014 2:00PM
MAIN BALLROOM

Private

Vasomune Therapeutics is a biotechnology company developing compounds targeting diseases associated with vascular dysfunction and destabilization. The company's lead compound is Vasculotide, a Tie2 receptor agonist that is being developed to treat Acute Kidney Injury (AKI). Vasomune has raised \$1.2 million in seed financing to support manufacturing, pharmacology, toxicology and a pre-IND meeting with the FDA to define a clear path to the clinic. The company's business model is to take its lead program through to Phase II clinical proof-of-concept prior to partnering.

viDA Therapeutics

JUNE 17, 2014 11:00AM
MAIN BALLROOM

Private

viDA Therapeutics, Inc. (viDA) is a platform-based, biotechnology company developing first-in-class therapeutics based on its recent discovery of a new mechanism of action for a well-characterized protease target, Granzyme B (GzmB). This emerging science is leading to new treatments in impaired tissue repair, fibrosis, inflammation and aging and is pivotal in understanding the underlying causes of diseases affecting vasculature, skin, musculoskeletal and potentially neurological systems. GzmB, one of a family of five serine proteases known as granzymes, is now emerging as a key target for drug development given recent discoveries of its extracellular actions, providing a clear distinction from GzmB's intracellular role in apoptosis. viDA is developing a library of granzyme inhibitors designed for multiple routes of administration to treat chronic and orphan skin conditions, fibrosis, autoimmune and cardiovascular disease.

Xagenic

JUNE 18, 2014 10:00AM
LOUNGE

Private

Xagenic is a privately held molecular diagnostics company developing a fully-automated molecular diagnostic platform that will enable lab-free testing with a time-to-result of 20 minutes. The company is developing a menu of infectious disease tests that will have a positive impact on patient care and reduce health care costs. The company is supported by private investors, including Domain Associates, CTI Life Sciences Fund and the Ontario Capital Growth Corporation.

Zymeworks

JUNE 18, 2014 9:30AM
LOUNGE

Private

Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. The company's novel Azymetric™ and AlbuCORE™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.



Bloom Burton exists to Accelerate Returns in Healthcare

The goal of all investors, companies and organizations is to achieve a monetizing event, such as the ability to raise capital, perform meaningful research and development, license or commercialize products, reach profitability or execute a strategic transaction.

The people who work at Bloom Burton have deep knowledge in medicine, science, patent and corporate law, finance and healthcare invention, development and commercialization.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade and, as a result of our deep expertise and experience, our clients achieve a faster path to their monetizing events.

Bloom Burton works with institutional and individual investors looking to invest in the healthcare sector. We also work with healthcare companies and organizations of all sizes and stages of development, who seek advice and capital.

As a result of our expertise and experience in healthcare, we have developed a disciplined methodology for helping companies grow faster. Our methodology, and all of the services we offer, rest on six key pillars: deeper due diligence, a broader range of investment options, greater understanding of cross-border rules, relationships with international healthcare-specialized investors, engagement with the broader healthcare community, and a creative, tenacious, entrepreneurial culture.

Our Services

Our services help identify, cultivate and create investment opportunities in the healthcare sector, on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, life science tools, animal health, nutrition and wellness.

Our six business services work cohesively to accelerate monetization for both company and investor clients:

- Raising capital and financing
- Mergers and acquisition advisory
- Equity Research
- Monetization Planning (both strategic and scientific consulting)
- Direct Investments through the Bloom Burton Funds
- Company Creation and Incubation

Let us know how we can help you accelerate your returns in the healthcare sector.



Private Placement
\$180,075,000



Special Warrants
April 2014
Selling Group

Private Placement
\$3,400,000



Common Shares
March 2014
Finder

Private Placement
\$3,000,000



Common Shares
March 2014
Finder

Private Placement
\$8,000,000



CannMedica Pharma™
Dispensing Relief

Units
March 2014
Financial Advisor

Private Placement
\$3,100,000



Units
March 2014
Finder

M&A Transaction
Not disclosed



Completes acquisition of



Advisor to Triton Pharma
January 2014

Private Placement
\$33,000,000



Units
December 2013
Agent

Public Offering
\$9,804,500



Units
September 2013
Selling Group

Private Equity Investment
Approx. \$17,000,000



September 2013
Advisor to STI

M&A Transaction
Approx. \$357,000,000



September 2013
Advisor to Medicago
Management

Private Placement
Up to \$4,000,000



Units
September 2013
Agent

Scientific Advisory



September 2013

BLOOM BURTON'S SELECT TRANSACTIONS

M&A Transaction

Approx. \$13,000,000



completes acquisition of



August 2013
Advisor to Thallion

Debt

US\$6,000,000



issues debt to



August 2013
Advisor to Tribute

Public Offering

\$40,000,000



TRIMEL
PHARMACEUTICALS

Common Shares
April 2013
Advisor

Scientific Advisory



January 2013

Strategic Advisory



December 2012

Private Placement

US\$12,500,000



Units
December 2012
Advisor

M&A Transaction

Approx. \$510,000,000



completes acquisition of



December 2012
Advisor to YM BioSciences

Strategic & Scientific
Advisory



October 2012

Venture Debt

\$7,500,000



issues debt to



TRIMEL
PHARMACEUTICALS

July 2012
Advisor to Trimel

Secured Debt

\$8,000,000



issues debt to



May 2012
Advisor to Nuvo

Bought Deal

\$21,276,150



Common Shares
February 2012
Selling Group

Public Offering

US\$80,500,000



Common Shares
February 2012
Advisor to YM



bloom burton & co

/accelerating returns in healthcare

